UPS Completes Acquisitions of Healthcare Cold-Chain Logistics Providers Frigo-Trans and BPL
UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe.
The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cryopreservation (-196°C) to ambient (+15° to +25°C) as well as Pan-European cold chain transportation. This combined with the logistics solutions brought by BPL’s time-critical freight forwarding capabilities further enhances UPS Healthcare solutions for customers in Europe.
For more information about UPS innovations and customer-driven solutions, visit about.ups.com.
About UPS
UPS (NYSE: UPS) is one of the world’s largest companies, with 2023 revenue of $91.0 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. More information can be found at www.ups.com, about.ups.com and www.investors.ups.com.
About UPS Healthcare
UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 17 million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices and lab and clinical trial logistics. UPS Healthcare's global infrastructure, UPS® Premier visibility service, track and trace technology and global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device and laboratory diagnostic industries. Visit Healthcare.ups.com for more information.
About Frigo-Trans
Frigo-Trans provides an end-to-end warehouse and transportation solution for pharmaceutical and biotech customers. Frigo-Trans does this by utilizing best-in-class distribution facilities and a pharmacy-focused, Pan-European, cold-chain transportation network. Other value-added services include, but are not limited to, packaging, handling and inventory management. Headquartered in Fußgönheim, Germany, Frigo-Trans’s network expands across all countries in Europe.
About BPL
BPL offers individual transport management for GDP-compliant shipping of time-critical and temperature-sensitive products. BPL manages a high-quality network of air and ocean freight carriers along with customs clearance to meet the complex, cross border needs of customers. BPL prioritizes serving biopharma customers with special temperature, quality and speed requirements. BPL is headquartered in Duesseldorf, Germany.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108660127/en/
Contacts
UPS Media Relations
pr@ups.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verne Appoints Michele Tagliatti as Chief Financial Officer9.1.2025 12:00:00 EET | Press release
Verne, a leading provider of sustainably powered HPC data centers across the Nordics, has announced the appointment of Michele Tagliatti as its Chief Financial Officer (CFO). With over 10 years of experience in the data center, telecommunications, and technology sectors, Tagliatti brings a wealth of knowledge to the role. He will focus on creating a results-based financial strategy that will be instrumental in driving Verne’s continued success as it scales its operations to meet the rising demand for cost-efficient, renewable-powered data center and colocation services for HPC and AI workloads. He will be based at Verne’s group headquarters in London. Before joining Verne, Tagliatti was at Liquid Intelligent Technologies, where he held several senior leadership roles, including Deputy Group Chief Financial Officer (DGCFO) and Group CFO of its data center business unit. During his tenure, he successfully led the financial restructuring and carve-out of the data center business unit, tha
Agile Data Engine Announces Built on Databricks Partner Status9.1.2025 11:15:00 EET | Press release
Agile Data Engine (ADE), provider of the all-in-one SaaS DataOps Development and Operations Platform for development, provision and operation of data lakehouses, has now been awarded Built on Partner status by Databricks, the Data and AI company. ADE has become a Nordic powerhouse for helping customers to move legacy data platforms to agile and resilient data lakehouses. The company offers accelerated tools that reduce implementation time and labor, helping businesses realize value more quickly by streamlining the complex process of data platform transformation and providing efficient development and operational capabilities for data lakehouses. The Databricks Data Intelligence Platform democratizes access to analytics and intelligent applications by marrying customers’ data with powerful AI models tuned to the unique characteristics of their business. The platform is built on a lakehouse foundation of open data formats and open governance to ensure that all data is completely within t
Infobip Recognized as AIT Fraud Prevention Leader by Juniper Research9.1.2025 11:01:00 EET | Press release
Global cloud communications platform Infobip has been recognized as the number one provider among Established Leaders in the Artificially Inflated Traffic (AIT) Fraud Prevention market by Juniper Research. The analyst firm has ranked Infobip first of 18 vendors in its Competitor Leaderboard for AIT Fraud Detection Solution Vendors 2024. Juniper Research scores vendors across 11 criteria, including but not limited to their size of operations in the AIT prevention market, the extent and breadth of relevant partnerships, market coverage, and product strength. Infobip scored highly across each of these and three further categories. Overall, Infobip was ranked as the Leading firm because it offers a comprehensive solution to AIT fraud detection and prevention strategies, including its ‘Infobip Signals’ solution, which detects AIT by monitoring phone number behavior, ranges, and types. Helping set Infobip aside from others in the market is its use of artificial intelligence (AI) and machine
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy9.1.2025 10:00:00 EET | Press release
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for thetreatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy. “Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddl
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference9.1.2025 09:37:00 EET | Press release
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann Pick type C (NPC). Positive topline data reported earlier this year from the company’s successful Phase 2 study investigating nizubaglustat in GM2 and NPC patients demonstrated that the compound had a positive safety profile. Preliminary improvements or stabilization of clinical endpoints were observed in the majority of patients, highlighting encouraging early efficacy trends for the compound. Azafaros is preparing to initiate Phase 3 studies with nizubaglustat in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom